Management of hypothyroidism and hyperthyroidism

Czech version

Authors: Jan Jiskra
Authors‘ workplace: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2015; 61(10): 868-872
Category: Reviews

Overview

Functional thyropathies present significant health risks for patients. Advanced functional thyropathies are always treated while indications for therapy of subclinical thyropathies are individual and often controversial. It is widely agreed that these disorders should be diagnosed and individuals should be followed. The drug of choice in substitution therapy of hypothyroidism is levothyroxine, in the treatment of hyperthyroidism it is methimazole. Administration of propylthiouracil should be limited to the first trimester of pregnancy, because its serious hepatotoxicity has been described. Hyperthyroidism based on thyroid nodules and immunogenic hyperthyroidism not reaching long-term remission, need to be treated radically: by surgery or radioiodine treatment. When radiation protection requirements are met, radioiodine can also be administered on an outpatient basis. Exceptionally, small doses of methimazole can be administered over an extended period of time in individual cases.

Key words:
hyperthyroidism – hypothyroidism – levothyroxine – methimazole – propylthiouracil – radioiodine ¹³¹I – total thyroidectomy – thyroid stimulating hormone

Sources

1. Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. Endocrinol (Oxf) 2014; 81(5): 633–641.

2. Bahn RS, Burch HB, Cooper DS et al. American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17(3): 456–520.

3. Cooper DS, Doherty GM, Haugen BR et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19(11): 1167–1214.

4. DeGroot L, Abalovich M, Alexander EK et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society practice guidelines. J Clin Endocrinol Metab 2012; 97(8): 2543–2565.

5. Garber JR, Cobin RH, Gharib H et al. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18(6): 988–1028.

6. Jiskra J, Kubinyi J, Telička Z. Léčba hypertyreóza radiojódem 131I v ambulantním režimu – bezpečná, účinná a ekonomická varianta. Vnitř Lék 2012; 58(2): 94–98.

7. Jonklaas J, Bianco AC, Bauer AJ et al. Guidelines for the treatment of hypothyroidism. Thyroid 2014; 24(12):1670–1751.

8. Límanová Z et al. Doporučení pro diagnostiku a léčbu onemocnění štítné žlázy v těhotenství a pro ženy s poruchou fertility. Klin Biochem Metab 2013; 21(42): 41–64.

9. Malozowszki S, Chiesa A. Propylthiuracil-induced hepatotoxicity and death. Hopefully, never more. JCEM 2010; 95(7): 3161–3163.

10. Pearce SH, Brabant G, Duntas LH et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J 2013; 2(4): 215–228.

11. Wiersinga WM, Duntas L, Fadeyev V et al. 2012 ETA Guidelines: The use of LT4 + LT3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1(2): 55–71.

12. Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid 1999; 9(12): 1167–1174.

13. Zamrazil V. Nemoci štítné žlázy v klinické praxi. Postgraduální medicina 2013; 15(7): 720–729.